Market capitalization | $740.00k |
Enterprise Value | $12.02m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.99 |
P/S ratio (TTM) P/S ratio | 0.06 |
P/B ratio (TTM) P/B ratio | 0.39 |
Revenue growth (TTM) Revenue growth | -44.62% |
Revenue (TTM) Revenue | $12.12m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast SQZ Biotechnologies Co:
1 Analyst has issued a forecast SQZ Biotechnologies Co:
Sep '23 |
+/-
%
|
||
Revenue | 12 12 |
45%
45%
|
|
Gross Profit | 1.20 1.20 |
89%
89%
|
|
EBITDA | -50 -50 |
26%
26%
|
EBIT (Operating Income) EBIT | -61 -61 |
23%
23%
|
Net Profit | -72 -72 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. It operates through SQZ Cell Therapy Platform, which uses membrane disruption to deliver material into cells. The company was founded by Robert S. Langer Jr., Klavis F. Jensen, Agustin Lopez Marquez, and Armon Sharei in March 2013 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Howard Bernstein |
Founded | 2013 |
Website | www.sqzbiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.